Anticoagulation with vitamin k antagonists is the standard recommendation for patients with nonvalvular atrial fibrillation and risk factors for stroke. The benefits of warfarin in such patients have been well shown in many clinical trials. Therapy with warfarin, however, is often complicated by the dietary and drug interactions, so that even with frequent monitoring, precise control of the anticoagulation level is difficult.